BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study

被引：3
作者：
Rosa, Regis Goulart [1 ,2 ,3 ]
Falavigna, Maicon [2 ,3 ,4 ]
Manfio, Joselia Larger [3 ]
de Araujo, Cintia Laura Pereira [3 ]
Cohen, Mirian [3 ,5 ]
Barbosa, Gynara Rezende Gonzalez do Valle [3 ]
de Souza, Ana Paula [3 ]
Silva, Fernanda Kelly Romeiro [3 ]
Sganzerla, Daniel [3 ]
da Silva, Mariana Motta Dias [3 ]
Ferreira, Diogo [6 ]
Rodrigues, Cristina de Oliveira [7 ]
de Souza, Emanuel Maltempi [8 ]
de Oliveira, Jaqueline Carvalho [8 ]
Gradia, Daniela Fiori [8 ]
Brandalize, Ana Paula Carneiro [7 ]
Royer, Carla Adriane [8 ]
Luiz, Rafael Messias [7 ]
Kucharski, Gabriela Almeida [9 ]
Pedrotti, Fernando [9 ]
Valluri, Srinivas Rao [10 ]
Srivastava, Amit [10 ,11 ]
Juliao, Viviane Wal [10 ]
Melone, Olga Chameh [10 ]
Allen, Kristen E. [10 ]
Kyaw, Moe H. [10 ]
Spinardi, Julia [10 ]
Castillo, Graciela del Carmen Morales [10 ]
McLaughlin, John M. [10 ]
机构：
[1] Hosp Moinhos de Vento HMV, Internal Med Dept, Porto Alegre, RS, Brazil
[2] Inova Med, Res Unit, Porto Alegre, RS, Brazil
[3] HMV, Res Inst, Porto Alegre, RS, Brazil
[4] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[5] Fed Univ Rio Grande do Sul UFRGS, Porto Alegre, RS, Brazil
[6] Otus Solut, Porto Alegre, RS, Brazil
[7] Fed Univ Parana UFPR, Fac Med, Campus Toledo, Toledo, Brazil
[8] UFPR, Dept Biochem & Mol Biol, Dept Genet, Curitiba, Parana, Brazil
[9] Dept Hlth Toledo, Toledo, PR, Brazil
[10] Pfizer, Vaccines Med & Sci Affairs Emerging Markets, Collegeville, PA USA
[11] Orbital Therapeut, Cambridge, MA USA
来源：
VACCINE | 2023年 / 41卷 / 37期
关键词：
COVID-19; vaccines; BNT162; vaccine; SARS-CoV-2; variants; Treatment outcome;
D O I：
10.1016/j.vaccine.2023.07.038
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: Evidence regarding effectiveness of BNT162b2 mRNA COVID-19 vaccine against Omicron in Latin America is limited. We estimated BNT162b2 effectiveness against symptomatic COVID-19 in Brazil when Omicron was predominant. Methods: This prospective test-negative, case-control study was conducted in Toledo, Brazil, following a mass COVID-19 vaccination with BNT162b2. Patients were included if they were aged >= 12 years, sought care for acute respiratory symptoms in the public health system between November 3, 2021 and June 20, 2022, and were tested for SARS-CoV-2 using RT-PCR. In the primary analysis, we determined the effectiveness of two doses of BNT162b2 against symptomatic COVID-19. Results: A total of 4,574 were enrolled; of these, 1,758 patients (586 cases and 1,172 controls) were included in the primary analysis. Mean age was 27.7 years, 53.8 % were women, and 90.1 % had a Charlson comorbidity index of zero. Omicron accounted for >97 % of all identified SARS-CoV-2 variants, with BA.1 and BA.2 accounting for 84.3 % and 12.6 %, respectively. Overall adjusted estimate of two-dose vaccine effectiveness against symptomatic COVID-19 was 46.7 % (95 %CI, 19.9 %-64.6 %) after a median time between the second dose and
引用
收藏
页码：5461 / 5468
页数：8
相关论文
共 30 条
  • [1] Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
    Accorsi, Emma K.
    Britton, Amadea
    Fleming-Dutra, Katherine E.
    Smith, Zachary R.
    Shang, Nong
    Derado, Gordana
    Miller, Joseph
    Schrag, Stephanie J.
    Verani, Jennifer R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (07): : 639 - 651
  • [2] Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
  • [3] Brazilian Ministry of Health, COVID-19 vaccinometer
  • [4] Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes
    Buchan, Sarah A.
    Chung, Hannah
    Brown, Kevin A.
    Austin, Peter C.
    Fell, Deshayne B.
    Gubbay, Jonathan B.
    Nasreen, Sharifa
    Schwartz, Kevin L.
    Sundaram, Maria E.
    Tadrous, Mina
    Wilson, Kumanan
    Wilson, Sarah E.
    Kwong, Jeffrey C.
    [J]. JAMA NETWORK OPEN, 2022, 5 (09) : E2232760
  • [5] Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
    Canetti, Michal
    Barda, Noam
    Gilboa, Mayan
    Indenbaum, Victoria
    Mandelboim, Michal
    Gonen, Tal
    Asraf, Keren
    Weiss-Ottolenghi, Yael
    Amit, Sharon
    Doolman, Ram
    Mendelson, Ella
    Harats, Dror
    Freedman, Laurence S. S.
    Kreiss, Yitshak
    Lustig, Yaniv
    Regev-Yochay, Gili
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [6] A Bivalent Omicron-Containing Booster Vaccine against Covid-19
    Chalkias, Spyros
    Harper, Charles
    Vrbicky, Keith
    Walsh, Stephen R.
    Essink, Brandon
    Brosz, Adam
    McGhee, Nichole
    Tomassini, Joanne E.
    Chen, Xing
    Chang, Ying
    Sutherland, Andrea
    Montefiori, David C.
    Girard, Bethany
    Edwards, Darin K.
    Feng, Jing
    Zhou, Honghong
    Baden, Lindsey R.
    Miller, Jacqueline M.
    Das, Rituparna
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (14) : 1279 - 1291
  • [7] Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
    Cheng, Samuel M. S.
    Mok, Chris Ka Pun
    Leung, Yonna W. Y.
    Ng, Susanna S.
    Chan, Karl C. K.
    Ko, Fanny W.
    Chen, Chunke
    Yiu, Karen
    Lam, Bosco H. S.
    Lau, Eric H. Y.
    Chan, Ken K. P.
    Luk, Leo L. H.
    Li, John K. C.
    Tsang, Leo C. H.
    Poon, Leo L. M.
    Hui, David S. C.
    Peiris, Malik
    [J]. NATURE MEDICINE, 2022, 28 (03) : 486 - +
  • [8] Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
    Collie, Shirley
    Champion, Jared
    Moultrie, Harry
    Bekker, Linda-Gail
    Gray, Glenda
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) : 494 - 496
  • [9] Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
    Falsey, Ann R.
    Sobieszczyk, Magdalena E.
    Hirsch, Ian
    Sproule, Stephanie
    Robb, Merlin L.
    Corey, Lawrence
    Neuzil, Kathleen M.
    Hahn, William
    Hunt, Julie
    Mulligan, Mark J.
    McEvoy, Charlene
    DeJesus, Edwin
    Hassman, Michael
    Little, Susan J.
    Pahud, Barbara A.
    Durbin, Anna
    Pickrell, Paul
    Daar, Eric S.
    Bush, Larry
    Solis, Joel
    Carr, Quito Osuna
    Oyedele, Temitope
    Buchbinder, Susan
    Cowden, Jessica
    Vargas, Sergio L.
    Benavides, Alfredo Guerreros
    Call, Robert
    Keefer, Michael C.
    Kirkpatrick, Beth D.
    Pullman, John
    Tong, Tina
    Isaacs, Margaret Brewinski
    Benkeser, David
    Janes, Holly E.
    Nason, Martha C.
    Green, Justin A.
    Kelly, Elizabeth J.
    Maaske, Jill
    Mueller, Nancy
    Shoemaker, Kathryn
    Takas, Therese
    Marshall, Richard P.
    Pangalos, Menelas N.
    Villafana, Tonya
    Gonzalez-Lopez, Antonio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (25) : 2348 - 2360
  • [10] Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
    Florentino, Pilar T., V
    Millington, Tristan
    Cerqueira-Silva, Thiago
    Robertson, Chris
    Oliveira, Vinicius de Araujo
    Junior, Juracy B. S.
    Alves, Flavia J. O.
    Penna, Gerson O.
    Katikireddi, Srinivasa Vital
    Boaventura, Viviane S.
    Werneck, Guilherme L.
    Pearce, Neil
    McCowan, Colin
    Sullivan, Christopher
    Agrawal, Utkarsh
    Grange, Zoe
    Ritchie, Lewis D.
    Simpson, Colin R.
    Sheikh, Aziz
    Barreto, Mauricio L.
    Rudan, Igor
    Barral-Netto, Manoel
    Paixao, Enny S.
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (11) : 1577 - 1586
123